(NASDAQ: MRSN) Mersana Therapeutics's forecast annual revenue growth rate of -10.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Mersana Therapeutics's revenue in 2024 is $36,855,000.On average, 3 Wall Street analysts forecast MRSN's revenue for 2024 to be $6,190,456,356, with the lowest MRSN revenue forecast at $4,852,120,280, and the highest MRSN revenue forecast at $8,491,210,490. On average, 3 Wall Street analysts forecast MRSN's revenue for 2025 to be $4,823,735,376, with the lowest MRSN revenue forecast at $4,245,605,245, and the highest MRSN revenue forecast at $5,228,159,602.
In 2026, MRSN is forecast to generate $3,032,575,175 in revenue, with the lowest revenue forecast at $3,032,575,175 and the highest revenue forecast at $3,032,575,175.